… for the Study of Lung Cancer (IASLC) SCLC committee … the form of topotecan, amrubicin, or lurbinectedin (Zepzelca) … Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer; September … with relapsed small cell lung cancer (IDeate-Lung02). Clinical …

Among patients with small cell lung cancer (SCLC), treatment with Imdelltra ( … ), lurbinectedin (47 patients) and amrubicin (23 patients). Investigators stratified patients … 2L) treatment for small cell lung cancer (SCLC): Outcomes by chemotherapy-free …

… topotecan (n = 185), or amrubicin (n = 23). The primary … previously treated small cell lung cancer receiving tarlatamab: results … treatment for small cell lung cancer (SCLC): primary analysis … Tarlatamab in small-cell lung cancer after platinum-based …

… of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.1 … (Zepzelca; 21.2%), amrubicin (8.8%), DLL3-targeting … of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer; September … with relapsed small cell lung cancer (IDeate-Lung02). Clinical …

… drugs, including topotecan, lurbinectedin, or amrubicin. Results from the interim analysis … planned for World Lung Cancer Day Coinciding with World Lung Cancer Day on Aug … of immunotherapy in small-cell lung cancer healthcare. Greek contribution draws …

… transforming the treatment landscape for lung cancer, offering new hope for patients … with both small cell lung cancer (SCLC) and non-SCLC (NSCLC … ; Jazz), topotecan (Hycamtin; Sandoz), and amrubicin (Calsed; Nippon Kayaku). The results …

… with relapsed small-cell lung cancer (SCLC) compared to … patients with small-cell lung cancer (SCLC) whose disease … topotecan, lurbinectedin, or amrubicin, while producing improvements in … in Relapsed Small Cell Lung Cancer (DeLLphi-304). ClinicalTrials.gov …

… topotecan, lurbinectedin, or amrubicin. They were further stratified … in Relapsed Small Cell Lung Cancer (DeLLphi-304). National … in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301 … DLL3 in small cell lung cancer and other neuroendocrine carcinomas. …

… cytologically confirmed small cell lung cancer who experienced disease progression … topotecan (185 patients), or amrubicin (23 patients). Stratification factors … intended chemotherapy (topotecan/amrubicin versus lurbinectedin). Overall survival served …

… immunotherapies for our patients with lung cancer.” Rudin is deputy director of … = 47), topotecan (n = 185), or amrubicin (n = 23). Stratification factors included … ), and intended chemotherapy (topotecan/amrubicin vs lurbinectedin). OS served as …